COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,788 Articles (22,946 medRxiv, 8,842 bioRxiv)

Most recent first Previous |  Page 2366: Articles 23651-23660  | Next

Universal properties of the dynamics of the Covid-19 pandemics
Chrusciel, P. T., Szybka, S. J.
10.1101/2020.08.24.20181214 — Posted: 2020-08-29
Real-time, interactive website for US-county level Covid-19 event risk assessment
Chande, A., Lee, S., Harris, M., Hilley, T., Andris, C., Weitz, J. S.
10.1101/2020.08.24.20181271 — Posted: 2020-08-29
Where do Brazilian dental students seek information about COVID-19?
Brito Aragao, M. G., Fernandes Gomes, F. I., Siqueira Silva Coelho, C., Pinho Maia Paixao de Melo, L., Milori Corona, S. A.
10.1101/2020.08.24.20179614 — Posted: 2020-08-29
Prevalence of Venous Thromboembolism in Critically-ill COVID-19 Patients: Systematic Review and Meta-analysis
Mohamed, M. F. H., Al-Shokri, S. D., Shunnar, K. M., Mohamed, S. F., Najim, M. S., Ibrahim, S. I., Elewa, H., Dousa, K. M., Abdalla, L. O., El-Bardissy, A., Elshafei, M. N., Abubeker, I. Y., Danjuma, M., Yassin, M. A.
10.1101/2020.08.24.20175745 — Posted: 2020-08-29
Cellular immune response to SARS-CoV-2 infection in humans: a systematic review
Shrotri, M., van Schalkwyk, M. C. I., Post, N., Eddy, D., Huntley, C., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., Maher, J., Shields, A. M., Amirthalingam, G., Peacock, S. J., Ismail, S. A.
10.1101/2020.08.24.20180679 — Posted: 2020-08-29 Discussion: Onsite
Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany
Aziz, N. A., Corman, V. M., Echterhoff, A. K. C., Richter, A., Schmandke, A., Schmidt, M. L., Schmidt, T. H., De Vries, F. M., Drosten, C., Breteler, M. M. B.
10.1101/2020.08.24.20181206 — Posted: 2020-08-29 Discussion: Onsite
Resolvin D1 and D2 reduce SARS-Cov-2-induced inflammation in cystic fibrosis macrophages
Recchiuti, A., Patruno, S., Mattoscio, D., Isopi, E., Pomilio, A., Lamolinara, A., Iezzi, M., Pecce, R., Romano, M.
10.1101/2020.08.28.255463 — Posted: 2020-08-28
Sequence analysis of Indian SARS-CoV-2 isolates shows a stronger interaction of mutated receptor binding domain with ACE2 receptor
Dash, P., Turuk, J., Behera, S. K., Palo, S. K., Raghav, S., Ghosh, A., Sabat, J., Rath, S., Subhadra, S., Bhattacharya, D., Kanungo, S., Kshatri, J., Mishra, B. k., Dash, S., Mahapatra, N., Parida, A., Pati, S.
10.1101/2020.08.28.271601 — Posted: 2020-08-28 Discussion: Onsite
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
Ghahremanpour, M. M., Tirado-Rives, J., Deshmukh, M., Ippolito, J. A., Zhang, C.-H., Cabeza de Vaca, I., Liosi, M.-E., Anderson, K. S., Jorgensen, W. L.
10.1101/2020.08.28.271957 — Posted: 2020-08-28
Prunella vulgaris extract and suramin block SARS-coronavirus 2 virus Spike protein D614 and G614 variants mediated receptor association and virus entry in cell culture system
Ao, Z., Chan, M., Ouyang, M. J., Olukitibi, T. A., Mahmoudi, M., Kobasa, D., Yao, X.
10.1101/2020.08.28.270306 — Posted: 2020-08-28 Discussion: Onsite | Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).